$CDLX

Gupta Amit sold $47K of CDLX

Gupta Amit (Chief Executive Officer) sold 17,733 shares of Cardlytics, Inc. (CDLX) at an average of $2.64 ($2.53–$2.71) across 2 trades over 2026-10-01 to 2026-10-02.

Original reporting
SEC EDGAR · Gupta Amit
Published Oct 2, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDLX
Neutral
high confidence
Mentioned
$CDLX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDLXNeutralLow
01

Why it matters

The transaction is minor and unlikely to move the stock significantly.

02

Market read

Limited relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions or personal financial planning not disclosed.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; this filing reports a small sale by Cardlytics' CEO.

Company-level read

Ticker impact

$CDLXNeutralHigh confidence
Context

CEO Amit Gupta sold 17,733 shares for $46.7K, reducing his stake to 138,906 shares.

Expected impact

likely modest pressure as the market prices in the small insider sale

Evidence & confidence

The sale amount is under $50K and represents a small percentage of total holdings, limiting material impact.

Market effects

None significant; insider sale does not affect sector dynamics.

No regional impact.

Limited to Cardlytics investors.

Counterpoint

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Amit Gupta

    Chief Executive Officer of Cardlytics, Inc.

  • Cardlytics, Inc.

    US-listed advertising technology firm (ticker CDLX).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).